n-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide profile

N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide: Cardioprotective Agent; a small-molecule activator of aldehyde dehydrogenase-2 that reduces ischemic damage to the heart [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	831629
CHEMBL ID	465952
CHEBI ID	94988
SCHEMBL ID	503808
MeSH ID	M0524997

Synonym
OPREA1_166989
n-benzo[1,3]dioxol-5-ylmethyl-2,6-dichloro-benzamide
MLS001206840
smr000518092
n-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide
STK417030
CHEMBL465952 ,
AKOS000648901
bxb ,
HMS2847P05
S5800
CS-4995
SCHEMBL503808
alda 1
349438-38-6
AC-35356
benzamide, n-(1,3-benzodioxol-5-ylmethyl)-2,6-dichloro-
alda-1
HY-18936
n-(benzo[d][1,3]dioxol-5-ylmethyl)-2,6-dichlorobenzamide
n-[(2h-1,3-benzodioxol-5-yl)methyl]-2,6-dichlorobenzamide
CHEBI:94988
alda-1, >=98% (hplc)
alda1
EX-A3557
BCP17146
Q27166749
BS-16611
BB 0300764
C74792
aldh2 agonist, alda-1
ZNA43838
bdbm50557071
DTXSID801324445

Excerpt	Reference	Relevance
"Cyclophosphamide (CY)-induced acute cardiotoxicity is a common side effect which is dose dependent."	( Aldehyde dehydrogenase 2 activation ameliorates cyclophosphamide-induced acute cardiotoxicity via detoxification of toxic aldehydes and suppression of cardiac cell death. Chen, Y; Fan, X; Liu, W; Wang, J; Wang, W; Zhai, X; Zhang, Z; Zheng, B, 2018)	0.48
" About 45% of Han Chinese (East Asians), accounting for 8% of humans, carry a single point mutation in ALDH2*2 (E504K) that leads to accumulation of toxic reactive aldehydes."	( Novel and prevalent non-East Asian ALDH2 variants; Implications for global susceptibility to aldehydes' toxicity. Barrientos, FL; Cervantes, PR; Chen, CH; Ferreira, JCB; Ferreira, ND; Hsu, JH; Joshi, AU; Li, SJ; Maclean, R; Martinez, DD; Mochly-Rosen, D; Quintanares, GHR; Stevens, MC, 2020)	0.56

Class	Description
carbonyl compound	Any compound containing the carbonyl group, C=O. The term is commonly used in the restricted sense of aldehydes and ketones, although it actually includes carboxylic acids and derivatives.
organohalogen compound	A compound containing at least one carbon-halogen bond (where X is a halogen atom).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
thioredoxin glutathione reductase	Schistosoma mansoni	Potency	0.1995	0.1000	22.9075	100.0000	AID485364
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	89.1251	0.0501	27.0736	89.1251	AID588590
Guanine nucleotide-binding protein G	Homo sapiens (human)	Potency	2.5119	1.9953	25.5327	50.1187	AID624288
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Aldehyde dehydrogenase, mitochondrial	Homo sapiens (human)	EC50 (µMol)	4.3000	4.3000	4.3000	4.3000	AID1707630
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
carbohydrate metabolic process	Aldehyde dehydrogenase, mitochondrial	Homo sapiens (human)
alcohol metabolic process	Aldehyde dehydrogenase, mitochondrial	Homo sapiens (human)
ethanol catabolic process	Aldehyde dehydrogenase, mitochondrial	Homo sapiens (human)
aldehyde catabolic process	Aldehyde dehydrogenase, mitochondrial	Homo sapiens (human)
regulation of dopamine biosynthetic process	Aldehyde dehydrogenase, mitochondrial	Homo sapiens (human)
regulation of serotonin biosynthetic process	Aldehyde dehydrogenase, mitochondrial	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
renal water homeostasis	Guanine nucleotide-binding protein G	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Guanine nucleotide-binding protein G	Homo sapiens (human)
regulation of insulin secretion	Guanine nucleotide-binding protein G	Homo sapiens (human)
cellular response to glucagon stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
aldehyde dehydrogenase (NAD+) activity	Aldehyde dehydrogenase, mitochondrial	Homo sapiens (human)
aldehyde dehydrogenase [NAD(P)+] activity	Aldehyde dehydrogenase, mitochondrial	Homo sapiens (human)
phenylacetaldehyde dehydrogenase activity	Aldehyde dehydrogenase, mitochondrial	Homo sapiens (human)
electron transfer activity	Aldehyde dehydrogenase, mitochondrial	Homo sapiens (human)
nitroglycerin reductase activity	Aldehyde dehydrogenase, mitochondrial	Homo sapiens (human)
glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity	Aldehyde dehydrogenase, mitochondrial	Homo sapiens (human)
NAD binding	Aldehyde dehydrogenase, mitochondrial	Homo sapiens (human)
carboxylesterase activity	Aldehyde dehydrogenase, mitochondrial	Homo sapiens (human)
G protein activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
adenylate cyclase activator activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
mitochondrion	Aldehyde dehydrogenase, mitochondrial	Homo sapiens (human)
mitochondrial matrix	Aldehyde dehydrogenase, mitochondrial	Homo sapiens (human)
extracellular exosome	Aldehyde dehydrogenase, mitochondrial	Homo sapiens (human)
plasma membrane	Guanine nucleotide-binding protein G	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (39)

Assay ID	Title	Year	Journal	Article
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID395251	Increase in human recombinant ALDH2*2 E487K mutant activity expressed in Escherichia coli BL21 cells	2008	Science (New York, N.Y.), Sep-12, Volume: 321, Issue:5895	Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
AID395243	Activation of human ALDH2 assessed as phosphorylated enzyme at 20 uM in absence of rat PKCepsilon by spectrophotometry	2008	Science (New York, N.Y.), Sep-12, Volume: 321, Issue:5895	Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
AID395253	Increase in wild type human recombinant ALDH21/1 homotetramer activity expressed in Escherichia coli BL21 cells using wild type allele relative to basal activity	2008	Science (New York, N.Y.), Sep-12, Volume: 321, Issue:5895	Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
AID395256	Ex vivo cardiac protection in Langendorff perfused Wistar rat heart assessed decrease in myocardial infarct size at 20 uM treated 35 mins before ischemia followed by 60 mins reperfusion by TTC staining	2008	Science (New York, N.Y.), Sep-12, Volume: 321, Issue:5895	Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
AID394516	Induction of cell-stress in Wistar rat heart assessed as JNK activation at 8.5 mg/kg after 5 mind by Western blot analysis	2008	Science (New York, N.Y.), Sep-12, Volume: 321, Issue:5895	Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
AID1762970	Anti-myocardial fibrosis activity against cardiac fibroblasts (unknown origin) assessed as reduction in collagen synthesis by measuring reduction in type3 collagen protein expression at 30 uM measured after 24 hrs by western blot analysis	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Magnolol, a natural aldehyde dehydrogenase-2 agonist, inhibits the proliferation and collagen synthesis of cardiac fibroblasts.
AID395250	Effect on human recombinant his-tagged mitochondrial ALDH5 activity expressed in Escherichia coli BL21 cells at 100 uM	2008	Science (New York, N.Y.), Sep-12, Volume: 321, Issue:5895	Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
AID1707630	Allosteric activation of recombinant human full-length ALDH2 (18 to 517 residues) expressed in Escherichia coli using acetaldehyde as substrate measured after 3 hrs in presence of NAD+ by fluorescence assay	2021	European journal of medicinal chemistry, Feb-15, Volume: 212	The discovery of novel small molecule allosteric activators of aldehyde dehydrogenase 2.
AID1762965	Anti-myocardial fibrosis activity against cardiac fibroblasts (unknown origin) assessed as inhibition of cell viability at 30 uM measured after 24 hrs by MTT assay	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Magnolol, a natural aldehyde dehydrogenase-2 agonist, inhibits the proliferation and collagen synthesis of cardiac fibroblasts.
AID1762969	Anti-myocardial fibrosis activity against cardiac fibroblasts (unknown origin) assessed as reduction in collagen synthesis by measuring reduction in type1 collagen protein expression at 30 uM measured after 24 hrs by western blot analysis	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Magnolol, a natural aldehyde dehydrogenase-2 agonist, inhibits the proliferation and collagen synthesis of cardiac fibroblasts.
AID1762966	Anti-myocardial fibrosis activity against cardiac fibroblasts (unknown origin) assessed as inhibition of cell proliferation at 30 uM measured after 24 hrs by EdU incorporation based assay	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Magnolol, a natural aldehyde dehydrogenase-2 agonist, inhibits the proliferation and collagen synthesis of cardiac fibroblasts.
AID394517	Induction of cell-stress in Wistar rat heart assessed as JNK activation at 8.5 mg/kg after ischemia followed by reperfusion by occluding left anterior descending coronary artery ligation for 35 mins by Western blot analysis	2008	Science (New York, N.Y.), Sep-12, Volume: 321, Issue:5895	Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
AID394515	Toxicity in Wistar rat assessed as blood parameters at 6 mg/kg/day for 1 week	2008	Science (New York, N.Y.), Sep-12, Volume: 321, Issue:5895	Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
AID1707632	Protection against middle cerebral artery occlusion-induced Sprague-Dawley rat model of ischemic stroke-like event assessed as reduction in brain infarct size at 50 ug, icv pretreated for 5 mins followed by MCAO surgery for 2 hrs and subsequent reperfusio	2021	European journal of medicinal chemistry, Feb-15, Volume: 212	The discovery of novel small molecule allosteric activators of aldehyde dehydrogenase 2.
AID1762968	Anti-myocardial fibrosis activity against cardiac fibroblasts (unknown origin) assessed as reduction in cyclinD1 protein expression at 30 uM measured after 24 hrs by western blot analysis	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Magnolol, a natural aldehyde dehydrogenase-2 agonist, inhibits the proliferation and collagen synthesis of cardiac fibroblasts.
AID395244	Activation of human ALDH2 assessed as phosphorylated enzyme at 20 uM in presence of rat PKCepsilon by spectrophotometry	2008	Science (New York, N.Y.), Sep-12, Volume: 321, Issue:5895	Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
AID1762967	Anti-myocardial fibrosis activity against cardiac fibroblasts (unknown origin) assessed as reduction in CDK4 protein expression at 30 uM measured after 24 hrs by western blot analysis	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Magnolol, a natural aldehyde dehydrogenase-2 agonist, inhibits the proliferation and collagen synthesis of cardiac fibroblasts.
AID395257	Ex vivo cardiac protection in Langendorff perfused Wistar rat heart assessed decrease of CPK release at 20 uM treated 35 mins before ischemia followed by 60 mins reperfusion	2008	Science (New York, N.Y.), Sep-12, Volume: 321, Issue:5895	Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
AID395248	Effect on alcohol dehydrogenase 1 activity at 100 uM	2008	Science (New York, N.Y.), Sep-12, Volume: 321, Issue:5895	Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
AID394514	Toxicity in Wistar rat assessed as histopathology at 6 mg/kg/day for 1 week	2008	Science (New York, N.Y.), Sep-12, Volume: 321, Issue:5895	Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
AID395252	Increase in human recombinant ALDH21/2 E487K mutant heterotetramer activity expressed in Escherichia coli BL21 cells using wild type and mutant allele	2008	Science (New York, N.Y.), Sep-12, Volume: 321, Issue:5895	Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
AID395255	Activation of wild type human recombinant ALDH2*1 expressed Escherichia coli BL21 cells at 10 uM relative to control	2008	Science (New York, N.Y.), Sep-12, Volume: 321, Issue:5895	Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
AID395249	Effect on human recombinant his-tagged cytosolic ALDH1A1 activity expressed in Escherichia coli BL21 cells at 100 uM	2008	Science (New York, N.Y.), Sep-12, Volume: 321, Issue:5895	Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
AID395254	Activation of human recombinant ALDH2*2 E487K mutant expressed Escherichia coli BL21 cells at 10 uM relative to control	2008	Science (New York, N.Y.), Sep-12, Volume: 321, Issue:5895	Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
AID394513	Reduction of cardiac damage in acute myocardial infarction Wistar rat model assessed as decrease in myocardial infarction at 8.5 mg/kg treated 5 mins before ischemia by TTC staining	2008	Science (New York, N.Y.), Sep-12, Volume: 321, Issue:5895	Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
AID395258	Reduction of cardiac damage in acute myocardial infarction Wistar rat model assessed as decrease in infarct size at 8.5 mg/kg treated before left anterior descending coronary artery ligation measured after 35 mins of ischemia followed by 60 mins reperfusi	2008	Science (New York, N.Y.), Sep-12, Volume: 321, Issue:5895	Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (2.94)	29.6817
2010's	53 (77.94)	24.3611
2020's	13 (19.12)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (1.47%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	67 (98.53%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
acetaldehyde Acetaldehyde: A colorless, flammable liquid used in the manufacture of acetic acid, perfumes, and flavors. It is also an intermediate in the metabolism of alcohol. It has a general narcotic action and also causes irritation of mucous membranes. Large doses may cause death from respiratory paralysis.. acetaldehyde : The aldehyde formed from acetic acid by reduction of the carboxy group. It is the most abundant carcinogen in tobacco smoke.. aldehyde : A compound RC(=O)H, in which a carbonyl group is bonded to one hydrogen atom and to one R group.. acetyl group : A group, formally derived from acetic acid by dehydroxylation, which is fundamental to the biochemistry of all forms of life. When bound to coenzyme A, it is central to the metabolism of carbohydrates and fats.	3.96	4	aldehyde	carcinogenic agent; EC 3.5.1.4 (amidase) inhibitor; electron acceptor; Escherichia coli metabolite; human metabolite; mouse metabolite; mutagen; oxidising agent; Saccharomyces cerevisiae metabolite; teratogenic agent
adenine [no description available]	2.11	1	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
3,4-dihydroxyphenylacetic acid 3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.. (3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.. dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.	2.08	1	catechols; dihydroxyphenylacetic acid	human metabolite
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	2.17	1	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
formaldehyde paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy	3.01	1	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	2.25	1	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
pimagedine pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure. aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.	2.11	1	guanidines; one-carbon compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor; EC 1.4.3.4 (monoamine oxidase) inhibitor
ro 31-7549 Ro 31-7549: structure	2.05	1
nitroglycerin Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.	2.45	2	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
vinyl chloride Vinyl Chloride: A gas that has been used as an aerosol propellant and is the starting material for polyvinyl resins. Toxicity studies have shown various adverse effects, particularly the occurrence of liver neoplasms.. chloroethene : A monohaloethene that is ethene in which one of the hydrogens has been replaced by a chloro group.	2.21	1	chloroethenes; gas molecular entity; monohaloethene	carcinogenic agent
rotenone Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.	2.11	1	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
acrolein [no description available]	2.57	2	enal	herbicide; human xenobiotic metabolite; toxin
monocrotaline Monocrotaline: A pyrrolizidine alkaloid and a toxic plant constituent that poisons livestock and humans through the ingestion of contaminated grains and other foods. The alkaloid causes pulmonary artery hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature. Significant attenuation of the cardiopulmonary changes are noted after oral magnesium treatment.	2.15	1	pyrrolizidine alkaloid
cyanamide Cyanamide: A cyanide compound which has been used as a fertilizer, defoliant and in many manufacturing processes. It often occurs as the calcium salt, sometimes also referred to as cyanamide. The citrated calcium salt is used in the treatment of alcoholism.. cyanamide : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by an amino group.	2.5	2	nitrile; one-carbon compound	EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	2.88	3	dialdehyde	biomarker
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.15	1	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
methylnitrosourea Methylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-methyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by methyl and nitroso groups.	2.25	1	N-nitrosoureas	alkylating agent; carcinogenic agent; mutagen; teratogenic agent
cupric chloride cupric chloride: RN given refers to unlabeled parent cpd. copper(II) chloride : An inorganic chloride of copper in which the metal is in the +2 oxidation state.	2.13	1	copper molecular entity; inorganic chloride	EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor
magnolol [no description available]	2.31	1	biphenyls
s-nitrosoglutathione [no description available]	2.13	1	glutathione derivative; nitrosothio compound	bronchodilator agent; nitric oxide donor; platelet aggregation inhibitor; signalling molecule
daidzin daidzin: a potent, selective, and reversible inhibitor of human mitochondrial aldehyde dehydrogenase. daidzein 7-O-beta-D-glucoside : A glycosyloxyisoflavone that is daidzein attached to a beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage. It is used in the treatment of alcohol dependency (antidipsotropic).	2.85	3	7-hydroxyisoflavones 7-O-beta-D-glucoside; hydroxyisoflavone; monosaccharide derivative	plant metabolite
3,4-dihydroxyphenylacetaldehyde 3,4-dihydroxyphenylacetaldehyde : A phenylacetaldehyde in which the 3 and 4 positions of the phenyl group are substituted by hydroxy groups.	2.08	1	alpha-CH2-containing aldehyde; catechols; phenylacetaldehydes	Escherichia coli metabolite; human metabolite; mouse metabolite
wortmannin [no description available]	2.05	1	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	2.1	1	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	2.1	1	stilbene
nadp [no description available]	2.13	1
methyl-thiohydantoin-tryptophan methyl-thiohydantoin-tryptophan: structure in first source	2.17	1	organonitrogen compound; organooxygen compound
4-hydroxy-2-nonenal 4-hydroxy-2-nonenal: cytotoxic product from peroxidation of liver microsomal lipids; RN given refers to cpd without isomeric designation. 4-hydroxynon-2-enal : An enal consisting of non-2-ene having an oxo group at the 1-position and a hydroxy group at the 4-position.. 4-hydroxynonenal : A monounsaturated fatty aldehyde that is nonanal that has undergone dehydrogenation to introduce a double bond at any position in the aliphatic chain and in which a hydrogen at position 4 has been replaced by a hydroxy group.	5.26	14	4-hydroxynon-2-enal; 4-hydroxynonenal
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	2.53	2	cysteinium	fundamental metabolite
nad NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.	2.77	3	organophosphate oxoanion	cofactor; human metabolite; hydrogen acceptor; Saccharomyces cerevisiae metabolite
ceruletide Ceruletide: A specific decapeptide obtained from the skin of Hila caerulea, an Australian amphibian. Caerulein is similar in action and composition to CHOLECYSTOKININ. It stimulates gastric, biliary, and pancreatic secretion; and certain smooth muscle. It is used in paralytic ileus and as diagnostic aid in pancreatic malfunction.. ceruletide : A decapeptide comprising 5-oxoprolyl, glutamyl, aspartyl, O-sulfotyrosyl, threonyl, glycyl, tryptopyl, methionyl, aspartyl and phenylalaninamide residues in sequence. Found in the skins of certain Australian amphibians, it is an analogue of the gastrointestinal peptide hormone cholecystokinin and stimulates gastric, biliary, and pancreatic secretion. It is used in cases of paralysis of the intestine (paralytic ileus) and as a diagnostic aid in pancreatic malfunction.	2.25	1	oligopeptide	diagnostic agent; gastrointestinal drug
atractyloside Atractyloside: A glycoside of a kaurene type diterpene that is found in some plants including Atractylis gummifera (ATRACTYLIS); COFFEE; XANTHIUM, and CALLILEPIS. Toxicity is due to inhibition of ADENINE NUCLEOTIDE TRANSLOCASE.	2.11	1
srt1720 [no description available]	2.1	1
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	2.15	1
amyloid beta-peptides amyloid beta-protein (1-40): although acutely neurotoxic in both rat & monkey cerebral cortex, neuronal degeneration in primates resembles more closely to that found in Alzheimer's disease; amino acid sequence has been determined	2.08	1
3-methyladenine N3-methyladenine: structure in first source	2.11	1

Condition	Relationship Strength	Studies
Cardiovascular Stroke [description not available]	3.19	5
Injury, Myocardial Reperfusion [description not available]	2.98	4
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	3.19	5
Innate Inflammatory Response [description not available]	3.7	3
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	3.7	3
Cerebral Infarction, Middle Cerebral Artery [description not available]	2.31	1
Acute Ischemic Stroke [description not available]	2.31	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	5.37	19
Ischemic Stroke Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin.	2.31	1
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	2.31	1
Chronic Lung Injury [description not available]	2.21	1
Hemorrhagic Shock [description not available]	2.21	1
Cirrhosis, Liver [description not available]	2.21	1
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	2.21	1
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	2.59	2
Acute Edematous Pancreatitis [description not available]	2.25	1
Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.	2.25	1
Pigmentary Retinopathy [description not available]	2.25	1
Retinitis Pigmentosa Hereditary, progressive degeneration of the retina due to death of ROD PHOTORECEPTORS initially and subsequent death of CONE PHOTORECEPTORS. It is characterized by deposition of pigment in the retina.	2.25	1
Tendinitis Inflammation of TENDONS. It is characterized by the degeneration of tendons accompanied by an inflammatory repair response, fibroblastic proliferation, and formation of granulation tissue. Tendinitis is not a clinical diagnosis and can be confirmed only by histopathological findings.	2.25	1
Tendinopathy Clinical syndrome describing overuse tendon injuries characterized by a combination of PAIN, diffuse or localized swelling, and impaired performance.	2.25	1
Acute Liver Injury, Drug-Induced [description not available]	2.25	1
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	2.25	1
Alcoholic Intoxication An acute brain syndrome which results from the excessive ingestion of ETHANOL or ALCOHOLIC BEVERAGES.	2.25	1
Liver Dysfunction [description not available]	2.25	1
Injury, Ischemia-Reperfusion [description not available]	4.58	8
Liver Diseases Pathological processes of the LIVER.	2.25	1
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	4.58	8
Cardiac Toxicity [description not available]	2.63	2
Cardiac Diseases [description not available]	2.31	1
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	2.31	1
Cardiotoxicity Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.	2.63	2
Disease, Pulmonary [description not available]	2.15	1
Intestinal Diseases Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.	2.15	1
Lung Diseases Pathological processes involving any part of the LUNG.	2.15	1
Lung Injury, Acute [description not available]	2.58	2
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	2.58	2
Arteriosclerosis, Coronary [description not available]	2.17	1
Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.	2.17	1
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	2.17	1
Chronic Illness [description not available]	2.17	1
Cardiac Failure [description not available]	2.17	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.17	1
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	2.17	1
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	2.17	1
Alloxan Diabetes [description not available]	2.17	1
Diabetic Retinopathy Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.	2.17	1
Alcohol Abuse [description not available]	2.21	1
Alcohol Drinking Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.	2.63	2
Alcoholism A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)	2.21	1
Cirrhosis [description not available]	2.54	2
Cardiac Hypertrophy Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.	2.83	3
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	2.54	2
Cardiomegaly Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.	2.83	3
Atherogenesis [description not available]	2.54	2
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	2.54	2
Fatty Liver, Nonalcoholic [description not available]	2.54	2
Liver Steatosis [description not available]	2.21	1
Fatty Liver Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.	2.21	1
Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION.	2.54	2
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	2.25	1
Esophageal Squamous Cell Carcinoma A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.	2.25	1
Cancer of Esophagus [description not available]	2.25	1
Experimental Neoplasms [description not available]	2.25	1
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	2.25	1
Hyperoxia An abnormal increase in the amount of oxygen in the tissues and organs.	2.21	1
Anoxemia [description not available]	2.08	1
Heart Disease, Ischemic [description not available]	2.08	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.79	3
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	2.08	1
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	2.08	1
Cerebral Ischemia [description not available]	2.1	1
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	2.1	1
Atrial Remodeling Long-term changes in the electrophysiological parameters and/or anatomical structures of the HEART ATRIA that result from prolonged changes in atrial rate, often associated with ATRIAL FIBRILLATION or long periods of intense EXERCISE.	2.1	1
Autoimmune Diabetes [description not available]	2.11	1
Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.	2.11	1
Allodynia [description not available]	3.01	1
Acute Pain Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.	3.01	1
Autosomal Dominant Juvenile Parkinson Disease [description not available]	2.11	1
MPTP Neurotoxicity Syndrome [description not available]	2.11	1
Parkinsonian Disorders A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.	2.11	1
Aortic Diseases Pathological processes involving any part of the AORTA.	2.1	1
Disease Exacerbation [description not available]	2.11	1
Cardiomyopathies, Primary [description not available]	2.52	2
Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).	2.52	2
Alcoholic Fatty Liver [description not available]	2.11	1
Coma A profound state of unconsciousness associated with depressed cerebral activity from which the individual cannot be aroused. Coma generally occurs when there is dysfunction or injury involving both cerebral hemispheres or the brain stem RETICULAR FORMATION.	2.11	1
Fasting Hypoglycemia HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.	2.11	1
Hypoglycemia A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.	2.11	1
Depression, Endogenous [description not available]	2.13	1
Delayed Effects, Prenatal Exposure [description not available]	2.13	1
Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.	2.13	1
Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.	2.13	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.13	1
Starvation Lengthy and continuous deprivation of food. (Stedman, 25th ed)	2.13	1
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	2.13	1
Asystole [description not available]	2.5	2
Heart Arrest Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.	2.5	2
Pulmonary Hypertension [description not available]	2.15	1
Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.	2.15	1
Idiopathic Parkinson Disease [description not available]	2.08	1
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	2.08	1
Dermatitis, Radiation-Induced [description not available]	2.07	1
Radiodermatitis A cutaneous inflammatory reaction occurring as a result of exposure to ionizing radiation.	2.07	1

n-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide

Description

Cross-References

Synonyms (34)

Research Excerpts

Toxicity

Drug Classes (2)

Protein Targets (4)

Potency Measurements

Activation Measurements

Biological Processes (11)

Molecular Functions (10)

Ceullar Components (4)

Bioassays (39)

Research

Studies (68)

Market Indicators

Research Demand Index: 11.20

Study Types

n-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide

Description

Cross-References

Synonyms (34)

Research Excerpts

Toxicity

Drug Classes (2)

Protein Targets (4)

Potency Measurements

Activation Measurements

Biological Processes (11)

Molecular Functions (10)

Ceullar Components (4)

Bioassays (39)

Research

Studies (68)

Market Indicators

Research Demand Index: 11.20

Study Types

Related Drugs (36)

Related Conditions (104)